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Baseline
Characteristics
Current Smoker
(n=1939)
Not Current
Smoker
(n=6644) p-value
Mean age, years 59.6  9.6 65.6  10.4 <0.0001
BMI 28.7  5.4 29.7  5.8 <0.0001
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SConclusions: In patients on clopidogrel after DES, the concomitant administration of
CCB was associated with reduced platelet inhibition and increased post discharge
adverse events. However, CCB were not associated with adverse clinical events by
multivariable analysis, suggesting confounding by comorbidities and presenting
characteristics. Thus, CCB may be used as indicated in patients on clopidogrel after
DES.
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Background: In the ADAPT-DES study, clopidogrel hyporesponsiveness was
strongly related to the 1-year incidence of stent thrombosis and of myocardial
infarction after drug-eluting stents, was inversely related to major bleeding, and was
unrelated to mortality.
Methods: The impact of clopidogrel hyporesponsiveness may differ between stable
angina (SAP) and acute coronary syndromes (ACS). We addressed this issue in
a secondary analysis of ADAPT-DES.
Results: Out of the 8449 patients, 4101 (49%) presented with SAP. At 1-year, the
incidences in SAP vs. ACS were 0.5% vs. 1.1% for stent thrombosis (P<0.001), 7.5%
vs. 4.6% for bleeding (P<0.001), 2.7% vs. 3.5% for myocardial infarction (P¼0.057)
and 1.8% vs.1.9% for all-cause death (P¼0.60). In SAP, the relation of clopidogrel
hyporesponsiveness to stent thrombosis (adjusted HR 1.44 [0.53, 3.88]; P ¼ 0.47),
myocardial infarction (1.54 [1.02, 2.32], P¼0.038), bleeding (0.69 [0.54,0.90];
P¼0.005) and death (1.40 [0.83,2.34]; P¼0.21) was consistent with that in the entire
study. Due to the difference in event rates, the absolute difference in the incidence of
stent thrombosis according to clopidogrel responder status was substantially smaller in
SAP compared with ACS, whereas that in bleeding was substantially larger (Figure).
Conclusions: In SAP, therapies aimed at correction of clopidogrel hyporesponsive-
ness for prevention of stent thrombosis may cause a disproportionate increase in
bleeding.B50 JACC Vol 62/18/Suppl B j October 27–NovemTCT-157
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Background: In prior studies non-smokers have been reported to have reduced
clinical beneﬁt of clopidogrel treatment as compared to smokers. This new "smoker's
paradox" has been explained by the increase in the production of clopidogrel's active
metabolite in smokers. We examined this relationship in the large scale Assessment of
Dual Anti-Platelet Therapy with Drug-Eluting Stents (ADAPT-DES) study.
Methods: Patients had P2Y12 platelet reactivity testing using the VerifyNow point-
of-care assay after successful, non-complicated PCI with DES implantation. All
patients were treated with aspirin and clopidogrel, and were followed for 1 year.
Current smoking status was deﬁned as active smoking within 1 month prior to
enrollment.
Results: Of the 8,583 patients enrolled, 1,939 (22.6%) pts were current smokers and
6,644 (77.4%) were not. Major baseline characteristics, P2Y12 results and 1-year
events are summarized in the Table. By multivariable analysis, current smoking status
was inversely associated with platelet reactivity (p¼0.0002). In propensity-stratiﬁed
proportional hazards regression models, current smoking was independently associ-
ated with 1-year all-cause mortality (HR [95%CI ¼ [1.54 [1.00, 2.38], p¼0.048), but
not with stent thrombosis (HR [95%CI ¼ [1.11 [0.62, 2.00], p¼0.72) or major
bleeding (HR [95%CI ¼ [1.10 [0.86, 1.41], p¼0.43).Diabetes 25.0% 34.6% <0.0001
Acute coronary
syndrome
65.5% 47.6% <0.0001
VerifyNow P2Y12
Mean PRU 172.0  94.2 192.6  97.0 <0.0001
PRU > 208 36.9% 44.5% <0.0001
%inhibition 41.8  29.2 39.5  27.9 0.0023
1-Year Follow-up
Death 1.7% 2.0% 0.46
MI 3.5% 3.1% 0.40
MACE 6.5% 6.9% 0.52
Stent thrombosis
(deﬁnite/probable)
1.6% 1.4% 0.55
Major bleeding 4.9% 6.6% 0.0075Conclusions: Current smokers treated with clopidogrel after non-complicated PCI
have greater levels of platelet inhibition compared with non-smokers. However, after
adjustment for differences in baseline characteristics, smoking status was indepen-
dently associated with mortality at 1 year. This analysis does not support the existence
of clopidogrel-related "smoker's paradox".ber 1, 2013 j TCT Abstracts/POSTER/Antiplatelets and Antithrombins
